Scientists: Analysis of Beethoven’s Hair Reveals Possible Cause of Mysterious Ailments

(FILES) A figurine of German composer Ludwig van Beethoven is seen in the souvenir shop of the Beethovenhaus museum, in Baden bei Wien, Austria. (Photo by Joe Klamar / AFP)
(FILES) A figurine of German composer Ludwig van Beethoven is seen in the souvenir shop of the Beethovenhaus museum, in Baden bei Wien, Austria. (Photo by Joe Klamar / AFP)
TT

Scientists: Analysis of Beethoven’s Hair Reveals Possible Cause of Mysterious Ailments

(FILES) A figurine of German composer Ludwig van Beethoven is seen in the souvenir shop of the Beethovenhaus museum, in Baden bei Wien, Austria. (Photo by Joe Klamar / AFP)
(FILES) A figurine of German composer Ludwig van Beethoven is seen in the souvenir shop of the Beethovenhaus museum, in Baden bei Wien, Austria. (Photo by Joe Klamar / AFP)

High levels of lead detected in authenticated locks of Ludwig van Beethoven’s hair suggest that the composer had lead poisoning, according to new research.

In addition to hearing loss, the famed classical composer had recurring gastrointestinal complaints throughout his life, experienced two attacks of jaundice and faced severe liver disease, CNN reported.

It is believed that Beethoven died from liver and kidney disease at age 56.

The composer expressed his wish that his ailments be studied and shared so “as far as possible at least the world will be reconciled to me after my death.”

An international team of researchers set out nearly a decade ago to partially fulfill Beethoven’s wish by studying locks of his hair, CNN said. Using DNA analysis, the team determined which ones truly belonged to the composer and which were fraudulent, and sequenced Beethoven’s genome by analyzing his authenticated locks.

The findings, published in a March 2023 report, revealed that Beethoven had significant genetic risk factors for liver disease and a hepatitis B infection before his death. But the results didn’t provide any insights into the underlying causes of his deafness, which began in his 20s, or his gastrointestinal issues.

Beethoven’s genome was made publicly available, inviting researchers around the world to investigate lingering questions about Beethoven’s health.

Meanwhile, scientists continue to figuratively go over the authenticated locks of Beethoven’s hair with a fine-tooth comb, teasing out surprising insights.

In addition to high concentrations of lead, the latest findings showed arsenic and mercury that remain trapped in the composer’s strands nearly 200 years after his death, according to a new letter published Monday in the journal Clinical Chemistry. And the insights could provide new windows not only into understanding Beethoven’s chronic health ailments, but the complicated nuances of his life as a composer, CNN said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”